Biotech Values

[DewDiligence]

ILNS’ folksy shareholder leter seeks to deceive investors (#msg-75588964):

Every day we draw closer to the announcement of data results from the bapineuzumab and solanezumab Phase 3 studies. There is a great deal of speculation and anticipation regarding the results, which we expect will be reflected soon in the mainstream media. In the meantime, we are reintroducing Intellect to professional investors and the media, as we are part of this historic moment. While today we may be relatively unknown, our pioneering ANTISENILIN technology is at the heart of several of the Alzheimer's compounds in development. Accordingly, positive data will provide validation of our technology and raise our corporate profile.

Nowhere here does it say that ILNS will receive a royalty on sales of bapineuzumab or solanezumab (because they won’t), but that’s plainly the message the shareholder letter intends to convey. Caveat emptor!